Month: September 2024

Results from this trial are expected in 2025 SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. “We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence from the literature suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson’s disease and that microglial NLRP3 activation may play an important role in Parkinson’s...

LISHUI, China, Sept. 06, 2024 (GLOBE NEWSWIRE) — Lixiang Education Holding Co., Ltd. (NASDAQ: LXEH) (the “Company”), a prestigious private education service provider in China, today announced that Mr. Luoyuan Ye resigned as the Chief Financial Officer (“CFO”) of the Company with effect from August 31, 2024 and will remain as the consultant to the Company. Mr. Zhifu Yang was appointed as the CFO with effect from September 2, 2024. Mr. Zhifu Yang, aged 42, has over 15 years of work experience in financial accounting and financial management. Since October 2021, Mr. Yang has been acting as the chief financial officer in Beijing Pengxiang Tianxia Education Technology Co., Ltd. From October 2019 to October 2021, Mr. Yang worked in Zhi Jin Education Consulting Co., Ltd as the chief financial officer. Before entering into the vocational...

Petah Tikvah, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company that develops and sells advanced transportation safety solutions, today announced that Froneri extended its agreement with SaverOne and will update and equip SaverOne systems across its entire fleet of employee vehicles and distribution trucks in Israel. Froneri was among the first companies to install the SaverOne System within its fleet to counteract driver distraction, back in 2021. Froneri is a UK-headquartered and leading manufacturer of ice cream with global sales. The company is jointly owned by Nestle Worldwide and R&R Ice Cream. Mr. Ori Gilboa, CEO of SaverOne, commented, “We are delighted that Froneri, an early customer of ours, is expanding its use of the SaverOne System across its entire...

TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PF) (“PTX Metals” or the “Company”) announces that it will consolidate its common shares (the “Common Shares”) on the basis of four (4) pre consolidated Common Shares into one (1) post consolidated Common Share (the “Share Consolidation”), effective as of the open of business on September 11, 2024 (the “Effective Date“). As of the Effective Date, the Company will commence trading on the Canadian Securities Exchange (the “Exchange”) on a consolidated basis and the new CUSIP and ISIN number will be 69380V205 and CA69380V2057, respectively. The Share Consolidation will result in the number of issued and outstanding Common Shares being reduced from the current outstanding 370,213,062 Common Shares to approximately 92,553,265...

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression Arimoclomol was well tolerated during the Open Label Extension trial and Early Access Program with no safety signals identified PK modeling studies showed that administration of OLPRUVA while fasting vs fed results in higher drug exposure which may allow for lower effective dosages when taken without food CELEBRATION, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced the presentation of five posters at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium. Four posters...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences.Event: H.C. Wainwright 26th Annual Global Investment Conference (New York, NY)Presentation: September 9, 2024 at 2:00 p.m. ETFormat: Company presentation and one-on-one meetings   Event: 6th Annual Exosome-Based Therapeutic Summit (Boston, MA)Presentation: September 17-19, 2024Format: Company presentation and industry panel    Event: 2024 Cantor Fitzgerald’s Global Healthcare Conference (New York, NY)Presentation: September 18, 2024 at 8:35 a.m. ETFormat: Fireside chat and one-on-one meetings   Capricor...

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a partner monetization and customer acquisition solutions leader, today announced that Don Patrick, Chief Executive Officer, and Ryan Perfit, Interim Chief Financial Officer, will participate in the 17th Annual Barrington Research Virtual Fall Investment Conference on Thursday, September 12, 2024. Mr. Patrick and Mr. Perfit will be available for one-on-one meetings throughout the day. About Fluent, Inc.Fluent, Inc. (NASDAQ: FLNT) has been a leader in performance marketing since 2010, offering customer acquisition and partner monetization solutions that exceed client expectations. Leveraging untapped channels and diverse ad inventory across partner ecosystems and owned sites, Fluent connects brands with consumers at the most optimal moment, ensuring impactful...

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content JUPITER, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”), a wellness company behind the world’s first rapid alcohol reducer that lowers blood alcohol content (“BAC”) by supporting its metabolism in as little as 30 minutes, has announced the Notice of Allowance of for a U.S. patent that covers its newest clinically-backed formula. “This latest patent marks a significant milestone in Safety Shot’s quest to lead a brand-new category that the Company has created to solve alcohol related problems,” stated Safety Shot COO and co-owner of the patent, David Sandler. The Company’s family of patents aims to corroborate Safety Shot’s competitive advantage in the market which...

TORONTO, Ontario, Sept. 06, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce the filing and mailing of its management information circular (the “Circular”) with respect to the amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”). This Transaction will constitute a reverse takeover of Titan. “The Circular sets out a compelling case for shareholders to approve Titan’s reverse merger with Conavi,” commented Paul Cataford, Titan’s Interim CEO and Board Chair. “After a thorough review of a number of potential transaction partners, Conavi came out on top. We believe the proposed Transaction offers our current Shareholders an opportunity to partially own an exciting...